Ohio State University Comprehensive Cancer Center
🇺🇸United States
Identification of Novel Genetic Factors That Contribute to Risk for Breast Cancer
Completed
- Conditions
- Invasive Breast Cancer
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2023-01-25
- Target Recruit Count
- 4385
- Registration Number
- NCT00276120
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- Fallopian Tube CancerPeritoneal CancerOvarian Cancer
- Interventions
- First Posted Date
- 2005-12-21
- Last Posted Date
- 2015-04-30
- Target Recruit Count
- 45
- Registration Number
- NCT00267696
- Locations
- 🇺🇸
The Ohio State University & James Cancer Hospital, Columbus, Ohio, United States
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2017-12-26
- Target Recruit Count
- 57
- Registration Number
- NCT00230126
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2018-07-26
- Target Recruit Count
- 40
- Registration Number
- NCT00201864
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Non-Hodgkin's LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2018-03-12
- Target Recruit Count
- 25
- Registration Number
- NCT00201877
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
Phase 2
Completed
- Conditions
- Cancer of StomachStomach CancerEsophageal CancerEsophagus Cancer
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-12-06
- Target Recruit Count
- 80
- Registration Number
- NCT00201747
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2015-06-10
- Target Recruit Count
- 19
- Registration Number
- NCT00201799
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-04-27
- Target Recruit Count
- 8
- Registration Number
- NCT00201786
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2016-09-02
- Target Recruit Count
- 56
- Registration Number
- NCT00201708
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2017-12-06
- Target Recruit Count
- 6
- Registration Number
- NCT00201669
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath